azeliragon (TTP488) / Cantex Pharma, vTv Therapeutics  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
azeliragon (TTP488) / Cantex Pharma
STEADFAST, NCT02080364 / 2016-002005-19: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

Checkmark From post-hoc analyses of STEADFAST trial [screenshot]
Mar 2019 - Mar 2019: From post-hoc analyses of STEADFAST trial [screenshot]
Checkmark From STEADFAST trial at CTAD [screenshot]
Oct 2018 - Oct 2018: From STEADFAST trial at CTAD [screenshot]
Checkmark Efficacy results from Part B of STEADFAST study
More
Terminated
3
880
Europe, Canada, US, RoW
Azeliragon, TTP488, Placebo
vTv Therapeutics
Alzheimer's Disease
06/18
06/18
STEADFAST Extension, NCT02916056: 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease

Terminated
3
297
Canada, US
Azeliragon 5mg, TTP488
vTv Therapeutics
Alzheimer's Disease
06/18
06/18
2017-004065-27: Clinical Study to assess the Safety And Efficacy Of Investigational Medicinal Product Azeliragon (TTP488) In Patients With Mild Alzheimer's Disease who have previously completed a Clinical Trial with Azeliragon (TP488)

Not yet recruiting
3
800
Europe
Azeliragon, TTP488, Capsule, hard
vTv THERAPEUTICS LLC, vTv THERAPEUTICS LLC
MILD ALZHEIMER'S DISEASE, MILD ALZHEIMER'S DISEASE, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05815485: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Recruiting
2/3
144
US
Azeliragon, Placebo
Salim S. Hayek
COVID-19
04/26
04/26

Download Options